Equities research analysts expect that Krystal Biotech, Inc. (NASDAQ:KRYS) will report earnings per share of ($0.55) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Krystal Biotech’s earnings. The highest EPS estimate is ($0.50) and the lowest is ($0.64). Krystal Biotech reported earnings of ($0.31) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 77.4%. The business is scheduled to report its next quarterly earnings report on Tuesday, March 9th.
According to Zacks, analysts expect that Krystal Biotech will report full year earnings of ($1.74) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.68). For the next financial year, analysts forecast that the company will report earnings of ($2.53) per share, with EPS estimates ranging from ($2.97) to ($2.05). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Krystal Biotech.
A number of equities analysts have weighed in on the stock. HC Wainwright increased their price target on shares of Krystal Biotech from $68.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, January 8th. Jonestrading started coverage on shares of Krystal Biotech in a report on Tuesday, February 9th. They set a “buy” rating and a $97.00 price objective for the company. Zacks Investment Research raised shares of Krystal Biotech from a “sell” rating to a “hold” rating in a report on Wednesday, January 13th. Finally, B. Riley reiterated a “buy” rating and set a $100.00 price target on shares of Krystal Biotech in a research report on Wednesday, November 11th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $91.17.
A number of institutional investors have recently made changes to their positions in KRYS. Victory Capital Management Inc. boosted its position in Krystal Biotech by 88.5% during the third quarter. Victory Capital Management Inc. now owns 524,144 shares of the company’s stock worth $22,565,000 after purchasing an additional 246,047 shares during the period. BlackRock Inc. boosted its position in Krystal Biotech by 17.6% during the fourth quarter. BlackRock Inc. now owns 1,407,348 shares of the company’s stock worth $84,441,000 after purchasing an additional 210,428 shares during the period. FIL Ltd boosted its position in Krystal Biotech by 295.8% during the fourth quarter. FIL Ltd now owns 241,326 shares of the company’s stock worth $14,480,000 after purchasing an additional 180,350 shares during the period. JPMorgan Chase & Co. boosted its position in Krystal Biotech by 178.8% during the fourth quarter. JPMorgan Chase & Co. now owns 239,312 shares of the company’s stock worth $14,359,000 after purchasing an additional 153,490 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Krystal Biotech by 23.1% during the third quarter. Point72 Asset Management L.P. now owns 663,889 shares of the company’s stock worth $28,580,000 after purchasing an additional 124,647 shares during the period. 73.05% of the stock is owned by hedge funds and other institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa.
Read More: Basic Economics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.